Mealer, Robert G. http://orcid.org/0000-0001-5963-2836
Williams, Sarah E. http://orcid.org/0000-0003-3624-611X
Noel, Maxence http://orcid.org/0000-0003-2621-7374
Yang, Bo http://orcid.org/0000-0003-3534-7517
D’Souza, Alexandria K.
Nakata, Toru
Graham, Daniel B.
Creasey, Elizabeth A.
Cetinbas, Murat
Sadreyev, Ruslan I.
Scolnick, Edward M.
Woo, Christina M.
Smoller, Jordan W. http://orcid.org/0000-0002-0381-6334
Xavier, Ramnik J. http://orcid.org/0000-0002-5630-5167
Cummings, Richard D.
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (T32MH112485)
Broad Institute | Stanley Center for Psychiatric Research, Broad Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute (U01CA242098)
Article History
Received: 23 February 2021
Revised: 7 February 2022
Accepted: 14 February 2022
First Online: 8 March 2022
Competing interests
: RJX is a cofounder and equity holder of Celsius Therapeutics and Jnana Therapeutics and consultant to Novartis. These companies did not provide support for this work. JWS is a member of the Scientific Advisory Board of Sensorium Therapeutics and has received honoraria for an internal seminar at Biogen, Inc and Tempus Labs. These companies did not provide support for this work. The remaining authors declare no competing interests.